Epigenomics AG reported earnings results for the first quarter ended March 31, 2013. First quarter 2013 revenues increased by 46% to EUR 355,000 compared to EUR 243,000 a year ago period, due to an increase in product sales (+31%) and R&D service fees. LBIT for the first quarter 2013 amounted to EUR 1.7 million compared EUR 2.3 million and net loss to EUR 1.7 million compared to EUR 2.3 million a year ago period, an improvement of about 26% each. Net cash flow in the first quarter 2013 was positive at EUR 2.8 million compared to net cash out flow of EUR 2.6 million for the same period a year ago. A major impact on liquidity resulted from the successful capital raise, through which Epigenomics recorded a net cash inflow of EUR 4.6 million. Cash outflow from operating activities was reduced to EUR 1.8 million compared to EUR 2.5 million a year ago period. The Company confirms its financial prognosis for the current business year as published in its Group management report for 2012. Prior to the approval of Epi proColon(R) as an IVD product in the U.S. market, Epigenomics remains cautious and does not expect revenue to increase significantly compared to 2012 levels. EBIT and net loss for 2013 are expected to be significantly lower than in 2012 as the effects of the 2011 restructuring measures now become fully visible as well as due to significantly reduced R&D expenses. Net loss and cash consumption for 2013 are both expected to be in the range of EUR 6.5 to 7.5 million. The most significant milestone for Epigenomics will be the expected U.S. approval for Epi proColon(R) by the FDA in the second half of 2013, in order to start the commercialization of the product in the most relevant market of the world. This approval will heavily affect the future value of the Company and its financial situation.

Epigenomics AG announced that Dr. Uwe Staub, Chief Operating Officer (COO) of the Company, has been appointed to the Executive Board, effective April 1, 2013. He will join the board as a second member next to Dr. Thomas Taapken, acting CEO and CFO of the company. Uwe Staub joined the company in November 2008 as Senior Vice President for Product Development and was promoted to COO in September 2012.

Epigenomics AG reported earnings results for the year ended December 31, 2012. For the period the company reported revenue of EUR 1.0 million against EUR 1.4 million for the same period last year generated from the product sales of EpiproColon kits, royalty payments, license income and partnering activities. Net loss was EUR 12.2 million against EUR 15.6 million for the same period last year. Prior to securing approval of Epi proColon as an IVD product in the U.S. market,  Epigenomics remains cautious and does not expect revenues to significantly differ from 2012 levels. EBIT and net loss for 2013 are expected to be significantly lower than in 2012 due to the full effect of the 2011 restructuring and significantly reduced R&D expenses. Net loss for 2013 expected in the range of EUR 6.5 to 7.5 million. In line with reduced net loss, cash consumption 2013 is expected to be in the range of EUR 6.5 to 7.5 million.